Effectiveness and safety of low-dose intraoperative tranexamic acid in cardiac surgery: a retrospective before-and-after study
Abstract
Tranexamic acid (TXA) is widely used to reduce perioperative bleeding and transfusion requirements; however, its optimal dosing, efficacy, and safety remain uncertain, particularly in cardiac surgery patients. This single-center, retrospective before-and-after study consecutively included adult patients who underwent cardiac and/or thoracic aortic surgery with cardiopulmonary bypass between 2011 and 2024. Patients were categorized into the before-TXA and after-TXA groups based on the implementation of a routine intraoperative low-dose TXA protocol in December 2017. This protocol included a loading dose (5 mg/kg) drawn from a 500 mg ampoule and administered at anesthesia induction, with the remaining dose added to the CPB priming volume. A maintenance infusion was administered at 5 mg/kg/h throughout surgery. The primary outcome was chest tube output during the first 12 h after surgery. Secondary safety outcomes included thrombotic complications and postoperative seizures. Outcomes were compared using interrupted time series analysis after stabilized inverse probability of treatment weighting. A total of 4,425 patients were analyzed (2,131 in the before-TXA group and 2,294 in the after-TXA group). The median (interquartile range) chest tube output during the first 12 h postoperatively was 480 mL (270–860 mL) in the before-TXA group and 400 mL (230–710 mL) in the after-TXA group. In the interrupted time series analysis, the intercept of log-transformed monthly chest tube…
Read the paper
Related studies
- Antioxidant efficacy and the upregulation of Nrf2-mediated HO-1 expression by (+)-lariciresinol, a lignan isolated from Rubia philippinensis, through the activation of p38
- Anti-influenza virus activity of green tea by-products in vitro and efficacy against influenza virus infection in chickens
- Therapeutic Potential of Mesenchymal Stem Cells (MSCs) and MSC-Derived Extracellular Vesicles for the Treatment of Spinal Cord Injury
- The intratumoral administration of ferucarbotran conjugated with doxorubicin improved therapeutic effect by magnetic hyperthermia combined with pharmacotherapy in a hepatocellular carcinoma model
- Enhanced anticancer efficacy of TRAIL-conjugated and odanacatib-loaded PLGA nanoparticles in TRAIL resistant cancer
- In vivo tracking of bioorthogonally labeled T-cells for predicting therapeutic efficacy of adoptive T-cell therapy
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.